Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT and Radium-223 in mCRPC
NCT04704505Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2022
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of testosterone cypionate and radium-223 dichloride in prostate adenocarcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Apr 2022; status: recruiting.
02
Drugs
testosterone cypionateradium-223 dichloride
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04704505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704505.